Sionna Therapeutics · 9 hours ago
Principal Scientist, CMC Analytical Development
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines for cystic fibrosis. They are seeking a Principal Analytical Scientist to lead CMC analytical activities, manage relationships with CDMO partners, and ensure compliance with regulatory guidelines for small molecule drug development.
BiotechnologyGeneticsHealth CareMedicalPharmaceuticalTherapeutics
Responsibilities
Work with CDMO partners for testing and release of starting materials, drug substance intermediates, API, drug products intermediates and final drug product to support Sionna clinical studies
Work with internal and external partners to develop and assign in-process/release specifications, and act as analytical point of contact during manufacturing activities
Work with partner teams to develop phase appropriate methods including validation/qualification for release starting materials, drug substance intermediates, API, drug products intermediates and final drug product. Manage transfer of analytical methods between CDMO partners
Manage stability studies for Sionna drug substances and drug products (experience with H&A Scientific SLIM a plus)
Coordinate CMC analytical activities with internal stakeholders (i.e., Discovery, Toxicology, Quality, Regulatory and Clinical) and external consultants
Complete technical review of reports and regulatory documents for US and ex-US filings
Qualification
Required
PhD in Chemistry or relevant discipline with 5+ years of small molecule analytical research and development experience, or MS with 10+ years of experience
Significant experience working CDMOs for the manufacturing and release of GMP small molecule DS and DP
Strong knowledge of regulatory CMC guidance documents relevant to analytical research and development (e.g. ICH Q7, M7, Q1A, Q1E, Q2, Q3A, Q3C, Q3D)
Expert knowledge of compendia (e.g., USP, EP, BP, etc.)
Working knowledge of other functions and links to CMC, for example Regulatory CMC, Toxicology, Quality, and Clinical
Outstanding verbal and written communication and collaboration skills within and among cross-functional teams and external organizations
Able to prioritize duties, manage multiple projects with limited supervision
Preferred
Experience with H&A Scientific SLIM
Company
Sionna Therapeutics
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Funding
Current Stage
Public CompanyTotal Funding
$292MKey Investors
Enavate SciencesOrbiMed
2025-02-07IPO
2024-03-06Series C· $182M
2022-04-19Series B· $110M
Leadership Team
Recent News
MarketScreener
2025-12-22
MarketScreener
2025-11-28
BioTech Breakthrough
2025-11-08
Company data provided by crunchbase